A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF ANG003 IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS
To evaluate safety and tolerability of a single orally delivered ANG003 dose in adult subjects with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) To evaluate four dose levels of ANG003 (4 lipase doses, 3 protease doses and 3 amylase doses) and select a dose(s) for Phase 2
